PCI will start with cytochrome P450 (CYP450) inhibitory IC50 testing across seven major enzyme isoforms (CYP3A4, CYP2D6, CYP2C9, CYP1A2, CYP2C19, CYP2B6, and CYP2E1), collectively responsible for metabolizing approximately 90% of marketed clinical drugs, supporting safe use, regulatory compliance, and consumer confidence. FDA and EMA guidelines recommend CYP inhibition evaluation for clinical and botanical drugs. PCI will make this service available to herbal and supplement manufacturers, pharmaceutical companies, and research institutions.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.